Sensorion completes a new funding round, for an amount of up to € 4 million, to begin the human clinical trial phase

Read

Sensorion and Griffin Discoveries awarded Eurostars grant for development of new therapies for vestibular disorders

Read

Palau Pharma signs an exclusive option agreement with Sensorion Pharmaceuticals for the development of Palau´s histamine-4 receptor antagonist, UR-63325, for the treatment of vestibular disorders

Read

Laurent Nguyen joins Sensorion as Chief Executive Officer and Eric de La Fortelle joins its Board of Directors

Read

Pipeline

2018 08 Pipeline

Enregistrer

Patient center

Corporate presentation

Next events